Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1994 Feb;57(2):180–185. doi: 10.1136/jnnp.57.2.180

HMPAO SPECT in Parkinson's disease before and after levodopa: correlation with dopaminergic responsiveness.

H S Markus 1, D C Costa 1, A J Lees 1
PMCID: PMC1072446  PMID: 8126501

Abstract

Regional cerebral perfusion was evaluated by SPECT with technetium 99m hexamethylpropyleneamine oxime (99mTc HMPAO) as a tracer in 21 patients presenting with Parkinson's disease and in 11 normal controls. In the parkinsonian patients, scans were performed both off treatment, and after levodopa, and clinical dopaminergic responsiveness was evaluated. Uptake of HMPAO by the basal ganglia was significantly decreased in the parkinsonian subjects, compared with normal controls. This reduction was seen in both responders (n = 14) and non-responders (n = 7) to dopaminergic treatment. Uptake of HMPAO by the basal ganglia rose after treatment with levodopa, but the change was similar in both responders and non-responders. By contrast a striking difference in cortical HMPAO uptake was found between responders and non-responders, with significantly lower uptake in the medial temporal and posterior parietal cortex in the non-responders. This reduction was symmetrical. Basal ganglia perfusion assessed by this technique is unlikely to be of use in the diagnosis of Parkinson's disease that is responsive to dopaminergic treatment. The presence of extensive cortical involvement on a baseline scan correlates with a lack of dopaminergic responsiveness, however, and this may be useful diagnostically.

Full text

PDF
180

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Blin J., Baron J. C., Dubois B., Pillon B., Cambon H., Cambier J., Agid Y. Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations. Arch Neurol. 1990 Jul;47(7):747–752. doi: 10.1001/archneur.1990.00530070035009. [DOI] [PubMed] [Google Scholar]
  2. Brooks D. J., Frackowiak R. S. PET and movement disorders. J Neurol Neurosurg Psychiatry. 1989 Jun;Suppl:68–77. doi: 10.1136/jnnp.52.suppl.68. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Brooks D. J., Ibanez V., Sawle G. V., Quinn N., Lees A. J., Mathias C. J., Bannister R., Marsden C. D., Frackowiak R. S. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol. 1990 Oct;28(4):547–555. doi: 10.1002/ana.410280412. [DOI] [PubMed] [Google Scholar]
  4. Costa D. C., Ell P. J., Burns A., Philpot M., Levy R. CBF tomograms with [99mTc-HM-PAO in patients with dementia (Alzheimer type and HIV) and Parkinson's disease--initial results. J Cereb Blood Flow Metab. 1988 Dec;8(6):S109–S115. doi: 10.1038/jcbfm.1988.40. [DOI] [PubMed] [Google Scholar]
  5. Elston J. S. The management of blepharospasm and hemifacial spasm. J Neurol. 1992 Jan;239(1):5–8. doi: 10.1007/BF00839203. [DOI] [PubMed] [Google Scholar]
  6. Frackowiak R. S., Pozzilli C., Legg N. J., Du Boulay G. H., Marshall J., Lenzi G. L., Jones T. Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain. 1981 Dec;104(Pt 4):753–778. doi: 10.1093/brain/104.4.753. [DOI] [PubMed] [Google Scholar]
  7. Gibb W. R. Neuropathology in movement disorders. J Neurol Neurosurg Psychiatry. 1989 Jun;Suppl:55–67. doi: 10.1136/jnnp.52.suppl.55. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Granérus A. K., Nilsson N. J., Suurküla M., Svanborg A. Cerebral blood flow in Parkinson's syndrome. Adv Neurol. 1984;40:403–405. [PubMed] [Google Scholar]
  9. Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression and mortality. Neurology. 1967 May;17(5):427–442. doi: 10.1212/wnl.17.5.427. [DOI] [PubMed] [Google Scholar]
  10. Hughes A. J., Daniel S. E., Kilford L., Lees A. J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181–184. doi: 10.1136/jnnp.55.3.181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hughes A. J., Lees A. J., Stern G. M. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes. Lancet. 1990 Jul 7;336(8706):32–34. doi: 10.1016/0140-6736(90)91531-e. [DOI] [PubMed] [Google Scholar]
  12. Kempster P. A., Frankel J. P., Bovingdon M., Webster R., Lees A. J., Stern G. M. Levodopa peripheral pharmacokinetics and duration of motor response in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1989 Jun;52(6):718–723. doi: 10.1136/jnnp.52.6.718. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Koller W. C. How accurately can Parkinson's disease be diagnosed? Neurology. 1992 Jan;42(1 Suppl 1):6–60. [PubMed] [Google Scholar]
  14. Kouris K., Jarritt P. H., Costa D. C., Ell P. J. Physical assessment of the GE/CGR Neurocam and comparison with a single rotating gamma-camera. Eur J Nucl Med. 1992;19(4):236–242. doi: 10.1007/BF00175135. [DOI] [PubMed] [Google Scholar]
  15. Leenders K. L., Wolfson L., Gibbs J. M., Wise R. J., Causon R., Jones T., Legg N. J. The effects of L-DOPA on regional cerebral blood flow and oxygen metabolism in patients with Parkinson's disease. Brain. 1985 Mar;108(Pt 1):171–191. doi: 10.1093/brain/108.1.171. [DOI] [PubMed] [Google Scholar]
  16. Martin W. R., Stoessl A. J., Adam M. J., Ammann W., Bergstrom M., Harrop R., Laihinen A., Rogers J. G., Ruth T. J., Sayre C. I. Positron emission tomography in Parkinson's disease: glucose and DOPA metabolism. Adv Neurol. 1987;45:95–98. [PubMed] [Google Scholar]
  17. Neirinckx R. D., Canning L. R., Piper I. M., Nowotnik D. P., Pickett R. D., Holmes R. A., Volkert W. A., Forster A. M., Weisner P. S., Marriott J. A. Technetium-99m d,l-HM-PAO: a new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion. J Nucl Med. 1987 Feb;28(2):191–202. [PubMed] [Google Scholar]
  18. Pizzolato G., Dam M., Borsato N., Saitta B., Da Col C., Perlotto N., Zanco P., Ferlin G., Battistin L. [99mTc]-HM-PAO SPECT in Parkinson's disease. J Cereb Blood Flow Metab. 1988 Dec;8(6):S101–S108. doi: 10.1038/jcbfm.1988.39. [DOI] [PubMed] [Google Scholar]
  19. Sawle G. V., Brooks D. J., Marsden C. D., Frackowiak R. S. Corticobasal degeneration. A unique pattern of regional cortical oxygen hypometabolism and striatal fluorodopa uptake demonstrated by positron emission tomography. Brain. 1991 Feb;114(Pt 1B):541–556. doi: 10.1093/brain/114.1.541. [DOI] [PubMed] [Google Scholar]
  20. Smith F. W., Gemmell H. G., Sharp P. F., Besson J. A. Technetium-99m HMPAO imaging in patients with basal ganglia disease. Br J Radiol. 1988 Oct;61(730):914–920. doi: 10.1259/0007-1285-61-730-914. [DOI] [PubMed] [Google Scholar]
  21. Spampinato U., Habert M. O., Mas J. L., Bourdel M. C., Ziegler M., de Recondo J., Askienazy S., Rondot P. (99mTc)-HM-PAO SPECT and cognitive impairment in Parkinson's disease: a comparison with dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry. 1991 Sep;54(9):787–792. doi: 10.1136/jnnp.54.9.787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Wolfson L. I., Leenders K. L., Brown L. L., Jones T. Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease. Neurology. 1985 Oct;35(10):1399–1405. doi: 10.1212/wnl.35.10.1399. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES